Enoxaparin vs. nadroparin for venous thromboembolism prevention: too close to tell?
Tosetto
A
A
Hematology Department, S. Bortolo Hospital, Vicenza, Italy. tosetto@hemato.ven.it
D000925:Anticoagulants / Q000494:pharmacology*; D002986:Clinical Trials as Topic; D003627:Data Interpretation, Statistical; D017984:Enoxaparin / Q000494:pharmacology*; D005343:Fibrinolytic Agents / Q000494:pharmacology*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006801:Humans; D017762:Nadroparin / Q000494:pharmacology*; D012107:Research Design; D012306:Risk; D013923:Thromboembolism / Q000188:drug therapy / Q000517:prevention & control*; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000188:drug therapy / Q000517:prevention & control*
D000925:Anticoagulants; D017984:Enoxaparin; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D017762:Nadroparin